+34 620 10 75 37info@nanbiosis.com

Nanbiosis

You are here : Home / 2019 (Page 7)

Preclinical molecular imaging and its application to biomedical research

During the days 22-24 of May is taking place in Madrid the 3rd Workshop of introduction to the preclinical molecular image and its application to biomedical research,. The wokshop has been organized by the Health Research Institute of the Gregorio Marañón Hospital, the Complutense University of Madrid and the Madrilenian Network of nanomedicine in molecular imaging (RENIM-CM).

The program counts with theoretical sessions of introduction to the physical foundations of each one of the modalities of image and its applications to preclinical biomedical research, as well as practical demonstrations of said image techniques.

Ibane Abásolo, Scientific Coordinator of Unit 20 of NANBIOSIS In Vivo Experimental Platform, introduced the in vivo optical imaging applications, explaining the research carried out at her research group at Vall d’Ebron Hospital Research Institute (VHIR) and NANBIOSIS U20 created by CIBER-BBN and VHIR, applied to projects as the H2020 Smart4Fabry and NoCanTher

NANBIOSIS U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section.

• Read More

An Eskimo in the desert

An Eskimo in the desert is the title of the talk that Ignacio Ochoa Researcher of NANBIOSIS U13 Tissue & Scaffold Characterization Unit is giving today at the Pint of Science Festival in Zaragoza at 19:00.

One of the greatest advances in biomedicine was to achieve, at the end of the 19th century, maintain human cells outside the body in order to study them. This breakthrough has allowed us, for example, to discover new drugs and evaluate the toxicity of many compounds. Unfortunately, this progress has hardly evolved over these 125 years. However, the arrival of microfluidic technology has allowed us to simulate much better what actually happens in our body. This new advance will revolutionize biomedicine, bringing it closer to the goal of personalized medicine

As Iñaki has explained to NANBIOSIS “Cells are accustomed to being in a specific environment in our body (mechanical, chemical, electrical, etc.) and, when we take them out of that environment to study them in the laboratories they stop working in a similar way as they did in vivo. This change of functioning sometimes generates false positives in the study of efficacy of new drugs and generates delays and excessive costs in the development of new treatments. Thanks to the Organ on Chip technology, we can better simulate in the laboratory the environment of the cells under physiopathological conditions (rigidities, gradients, flow or the presence of different cell types) and obtain results closer to the clinic”.

• Read More

DEVELOPING A SENSOR FRAMEWORK FOR MINIMALLY INVASIVE SURGERY

Francisco Miguel Sánchez Margallo, Scientific Director of the Minimally Invasive Surgery Center ‘Jesús Usón’ and Deputy Director of NANBIOSIS, leads, together with Thomas Malone, of the Massachusetts Institute of Technology (MIT), in the United States, the project selected by the MIT program -Spain ‘La Caixa’ Foundation Seed Fund “Developint a sensor framework for minimally invasive surgery”.

The project seeks to develop a system of sensors to analyze health parameters of the surgeon, such as his physiological and ergonomic state, as well as the interaction between this and the patient during surgery. It is a disruptive research project on sensors to improve the health of the surgeon and the quality of surgery. NANBIOSIS units at JUMISC will play an important role in the development of the project.

This program was born with the aim of promoting the interrelation between Spanish research groups of excellence and those of MIT. The initiative aims to generate synergies and facilitate collaboration in international projects with a pioneering entity at the international level such as MIT.

The collaboration with MIT brings great value to Spanish research, since it is one of the best international research institutions. Among the professors about 80 Nobel prizes are counted, and its students have promoted more than 30,000 companies.

• Read More

Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up (MAGRes)


Ana Paula Candiota, Scientific coordinator of U25 of NANBIOSIS, is the IP of the granted project Multiparametric MR approaches for non-invasive Glioblastoma therapy response follow-up (MAGRes), selected for funding in the ATTRACT call https://attract-eu.com/the-project/

The kick-off meeting for is taking place at CERN, Switzerland, days 20-21th May with talks of all selected projects. Unit 25 will have a relevant role in the development of MAGRes. MRI/MRSI from preclinical brain tumors will be acquired at NANBIOSIS U25, NMR: Biomedical Applications I

• Read More

U19-S02.

Animal Model Studies

This service is responsible for conducting regulatory studies for the pharmaceutical industry and interested companies. The safety and efficacy studies are carried out using small and large animal models for the different organic systems, also including animal models of different pathologies.

Customer benefits

These studies are carried out under strict quality regulations, certified with ISO-9001 and Good Laboratory Practices (GLP), quality standards that allow the production of high-precision results.
Therefore, safety and efficacy studies in animal models can be carried out in compliance with the strict guidelines of regulatory agencies, ensuring the reliability and traceability of all results and tests carried out in their different services.

Target customer

The services offered in this unit may be of interest to different companies and laboratories that work within the pharmaceutical industry. Companies whose objective is to test possible candidates for molecules, drugs or medical devices in animal models of specific pathologies.

References

  1. J Bote, et al. Novel ex-vivo database of a murine model of colorectal cancer using optical coherence tomography. Surg Endosc (2022) 36:S325–S674
  2. V Lucas-Cava, et al. Prostatic artery occlusion: Initial findings on pathophysiological response in a canine prostate model. Translational Andrology and Urology. Transl Androl Urol 2022.
  3. Soria F, et al. Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization-assessment in ureteral stricture endourological treatment in animal model. Transl Androl Urol. 2021 Apr;10(4):1700-1710.
  4. Baez-Díaz C, et al. Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model. Sci Rep. 2020 Apr 28;10(1):7166.
  5. Moreno-Lobato, B, et al. Use of nanomedicine in preclinical wound healing studies. FarmaJournal; Salamanca T 4, N.º 1, (Feb 2019): 178.
  6. Picado Román, N, et al. Drugs most used in experimental animals in a Research Center. FarmaJournal; Salamanca T 4, N.º 1, (Feb 2019): 236.
  7. Moreno-Lobato B, et al. Analytical Validation Study of Hematological Parameters under Good Laboratory Practice Regulations in Different Laboratory Animal Species. Thromb Haemost Res. 2019; 3(1): 1018.
  8. Ballestín A, et al. A Pre-clinical Rat Model for the Study of Ischemia reperfusion Injury in Reconstructive Microsurgery. J Vis Exp. 2019 Nov 8;(153).
  9. R Blázquez , et al. Altered hematological, biochemical and immunological parameters in a porcine myocardial infarction model: predictive biomarkers for the severity of myocardial infarction. Veterinary Immunology and Immunopathology 205 (2018) 49–57.
  10. Vela FJ, et al. Evaluation of antigen-induced synovitis in a porcine model: Immunological, arthroscopic and kinetic studies. BMC Vet Res. 2017. Apr 7;13(1):93.

• Read More

Job Vacancy for position of Project Manager at CIBER

Scientist aiming at developing a career in project management is required for a European Project in the field of biomedical research; working with NANBIOSIS ICTS (Scientific infraestructure of CIBER-BBN). The position requires good command of English and strong skills in coordinating researchers.

Applications must be filed at CIBER’s web portal untill May 22.

• Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSIS. Several units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

• Read More

Diabetes mellitus type 1: new system for treatment

The research carried out by the NanoBiocells group, coordinator of NANBIOSIS U10 Drug Formulation unit, from CIBER-BBN and UPV-EHU, with BIOMICS group of UPV-EHU was yesterday highlighted in Catalunya Vanguardista and Noticiasdelaciencia.com.

The research reduces the volume of implantation of microcapsules containing insulin-producing pancreatic cells by almost 80% thanks to an innovative system of Magnetic separation of microcapsules. In this way, the medical complications derived from the implantation of large volumes of microcapsules decrease and the treatment of type 1 diabetes mellitus improves.

More information:
https://www.catalunyavanguardista.com/nuevo-sistema-para-el-tratamiento-de-diabetes-mellitus-tipo-1/

• Read More

Biomedical devices with natural fluorescence for monitoring in the body

Researchers from the NanoBioCel and the ICTS NANBIOSIS through the Drug Formulation Unit 10 of CIBER-BBN and the University of the Basque Country (UPV/EHU), together with the University of Michigan (USA), have developed a biomedical cellular immunoisolation device (microcapsules) with intrinsic capacity to be traced once implanted in the organism. The novel design incorporates a natural substance called genipine, which emits intense and stable fluorescence in the far red range. Drug Formulation Unit 10 of Nanbiosis has worked in the design and development of fluorescent particles for use in experimental animals.

Non-invasive monitoring of implanted hydrogel-based biosystems generally requires indirect vehicle or load marking, which increases complexity and the potential risk of altering their functionality. For the first time, this group of researchers has demonstrated that hydrogel-based biosystems can be produced from biomaterials with intrinsic properties for non-invasive monitoring, in this case through the use of genipine.

The work has recently been published in the Journal of Biophotonics and has been selected by the journal as a cover story in April.

It is important to note that to date no one has exploited the natural fluorescence emitted by genipine as a non-invasive monitoring system in cell therapies implanted in living beings,” the researchers point out. As a first milestone in this sense, we have developed a novel immunoisolation device that incorporates genipine into its own design, making it traceable once implanted in the body. Using a fast, efficient and non-cytotoxic procedure, we have managed to maximize the fluorescence of the microcapsules until an excellent signal-to-noise ratio is achieved. In addition, the group have validated the use of genipine as a quantitative imaging probe, demonstrating that intense and stable fluorescence is obtained with good signal linearity against doses of microcapsules implanted for several weeks. Through this strategy, they have been able to evaluate the actual injected dose immediately and control its position over time, which significantly improves the biosafety and efficacy of the therapy.

In addition, the idea may have a potentially successful application in the nano, micro and macro hydrogel-based technologies industry. These are called to be fundamental pieces both for biomedical research and for the advancement of clinical medicine through applications such as tissue engineering, regenerative medicine. “As fluorescence imaging systems are gradually implemented in clinical practice, we believe that our proposal could have a successful applicability in advancing multiple hydrogel-based biotechnologies, including drug and cell delivery systems, vaccines or biosensors,” they conclude.

Article of reference :

Edorta Santos‐Vizcaino, Henry Haley, Ainhoa Gonzalez‐Pujana, Gorka Orive, Rosa Maria Hernandez, Gary D. Luker, Jose Luis Pedraz. Monitoring implantable immunoisolation devices with intrinsic fluorescence of genipin. Journal of Biophotonics (April 2019) DOI: https://doi.org/10.1002/jbio.201800170

• Read More

CIBER offers two Degree positions for NANBIOSIS (Project Mananger and Researcher) in the frame of a H2020 project.

CIBER-BBN offer two possitions for a project manager (PRF-1768 https://www.ciberisciii.es/empleo/detalle-oferta?id=1768 )  and a researcher (PRF-1766 https://www.ciberisciii.es/empleo/detalle-oferta?id=1766)

CIBER is looking for candidates for the selection of a project manager (https://www.ciberisciii.es/empleo/detalle-oferta?id=1768) and a researcher (ttps://www.ciberisciii.es/empleo/detalle-oferta?id=1766) to work in the framework of a European H2020 project.

SAFE-N-MEDTECH is an Open-Innovation Test Bed for Safety Testing of Medical Technologies for Health – H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing) medtech project, that has just been launched.

The project SAFE-N-MEDTECH will build an innovative open access platform providing reference laboratories and companies with the capabilities, know-how, networks and services needed for developing, testing, evaluating, optimizing and marketing nanotechnology and diagnostic medical devices throughout the products’ entire lifecycle.

It is a project with duration of 4 years in which 28 partners participate including CIBER-BBN through NANBIOSIS (www.nanbiosis.es), a Research Infrastructure (RI) recognized as Unique Scientific-Technological Infrastructure (ICTS) by the Spanish Government for the Design, production and characterization of biomaterials, nanomaterials and devices up to preclinical validation.

In the framework of this project, CIBER-BBN offer two contracts in Valencia to work under the guidance of the Project leader:

Candidates must register from the CIBER website www.ciberisciii.es  in the employment section, searching the BBN area for calls 1444/1766 and 1445/1768 UNTILL MAY, 22, 2019

For further information you can contact: 

-Ramón Martínez Mañez (Project leader) rmaez@qim.upv.es

-Nerea Argárate (NANBIOSIS Coordinator) nargarate@ciber-bbn.es

• Read More